Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2022-11-04 |
2022-09 |
-0.55 |
N/A |
N/A |
N/A |
2022-08-15 |
2022-06 |
-0.68 |
N/A |
N/A |
N/A |
2022-05-16 |
2022-03 |
-0.71 |
N/A |
N/A |
N/A |
2022-03-28 |
2021-12 |
-0.67 |
N/A |
N/A |
N/A |
2021-11-15 |
2021-09 |
-0.76 |
N/A |
N/A |
N/A |
2021-08-13 |
2021-06 |
-0.63 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2022-10-31 |
Oppenheimer |
Downgrade |
Outperform |
Perform |
2022-10-20 |
Roth Capital |
Downgrade |
Buy |
Sell |
2022-09-20 |
Noble Capital Markets |
Downgrade |
Outperform |
Market Perform |
2022-08-16 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2022-03-30 |
Oppenheimer |
Upgrade |
|
Outperform |
2022-03-30 |
Raymond James |
Upgrade |
|
Outperform |
Date |
Name |
Relation |
Quantity |
Description |
2020-05-11 |
AMOON 2 FUND LP |
Beneficial Owner of more than 10% of a Class of Security |
2.99M |
Purchase |
2022-05-15 |
GORDON GARY B |
Officer |
58.52K |
Stock Award(Grant) |
2020-05-11 |
HAREL INSURANCE CO. LTD |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2020-05-11 |
ISRAEL BIOTECH FUND I LP |
Beneficial Owner of more than 10% of a Class of Security |
3.32M |
Purchase |
2022-05-15 |
MAIMON YOSSI |
Chief Financial Officer |
69.87K |
Stock Award(Grant) |
2022-05-15 |
MAMLUK RONI |
Chief Executive Officer |
265.35K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2022-09-29 |
Harel Insurance Investments & Financial Services Ltd. |
2.15M |
1.15M |
14.53% |
2022-09-29 |
Bridgeway Capital Management, Inc. |
81.90K |
43.73K |
0.55% |
2022-09-29 |
CSS LLC |
64.18K |
34.27K |
0.43% |
2022-09-29 |
Psagot Value Holdings Ltd. / (Israel) |
61.01K |
32.57K |
0.41% |
2022-09-29 |
Renaissance Technologies, LLC |
48.00K |
25.63K |
0.32% |
2022-09-29 |
Clear Street LLC |
39.46K |
21.07K |
0.27% |
Report Date |
Organization |
Position |
Value |
Percentage |
2022-09-29 |
Bridgeway Funds Inc-Ultra Small Company Market Fund |
78.00K |
41.64K |
0.53% |
2022-10-30 |
Fidelity NASDAQ Composite Index Fund |
10.60K |
5.66K |
0.07% |